§ 01 Overview
Overview
Dual GLP-1 / glucagon receptor agonist showing strong weight loss and metabolic effects in late-stage trials, particularly in Asian populations.
Approved in China in 2025 for obesity and T2D. Ongoing trials in Western markets.
§ 02 Mechanism
Mechanism of action
Mazdutide activates both GLP-1 and glucagon receptors. The glucagon arm is hypothesized to increase energy expenditure and improve hepatic lipid handling, while GLP-1 drives appetite suppression and glycemic control.
- 01Substantial weight loss in Phase III (GLORY-1)
- 02Improvements in hepatic fat and liver enzymes
- 03Glycemic improvements in T2D
§ 03 Dosing
Dosing protocol
Standard Protocol
- Vial
- 10 mg
- BAC Water
- 1 ml BAC water
- Dose Range
- 3 – 9 mg weekly
- Starting Dose
- 3 mg weekly
- Route
- SubQ
- Frequency
- Weekly
- Cycle
- Titrate every 4 weeks.
§ 04 Evidence
Evidence & research
Approved in China in 2025 for obesity and T2D. Ongoing trials in Western markets.
FDA Status
Not FDA-approved. Approved in China (2025).
§ 06 News
In the news
8 articles from the last 12 months · updates hourly
Lilly’s Mazdutide AUD Trial Completion Signals New Optionality in Addiction Treatment - TipRanks
Lilly’s Mazdutide AUD Trial Completion Signals New Optionality in Addiction Treatment TipRanks
Mazdutide vs. Tirzepatide: What’s The Difference? - Forbes
Mazdutide vs. Tirzepatide: What’s The Difference? Forbes
Mazdutide Produces Significant Weight Loss in Adults with Obesity: JAMA - Medical Dialogues
Mazdutide Produces Significant Weight Loss in Adults with Obesity: JAMA Medical Dialogues
Innovent Biologics' study of mazdutide published by JAMA_News - sipac.gov.cn
Innovent Biologics' study of mazdutide published by JAMA_News sipac.gov.cn
Obesity drug mazdutide reduces weight and waist size in major trial - News-Medical
Obesity drug mazdutide reduces weight and waist size in major trial News-Medical
Mazdutide vs. Tirzepatide: Which Is Better for Weight Control? - Ro
Mazdutide vs. Tirzepatide: Which Is Better for Weight Control? Ro
China’s obesity drug makers take on global giants as Novo Nordisk patent expires - South China Morning Post
China’s obesity drug makers take on global giants as Novo Nordisk patent expires South China Morning Post
Mazdutide Outperforms Dulaglutide in Type 2 Diabetes Trial - EMJ
Mazdutide Outperforms Dulaglutide in Type 2 Diabetes Trial EMJ
§ 07 Sourcing
Sourcing & supply
Regulatory status
Investigational, no compounding path
Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk.
Research-use-only · 2
Swiss Chems
Established SARMs/peptide vendor. FDA warning letter Dec 2024 for GLP-1s. Weaker peptide QC than SARMs QC.
Summit Research
FDA warning letter December 2024 across multiple GLP-1s.
Listings are informational, not endorsement. Verify credentials and flags against FDA and PCAB databases before purchasing. Full directory & how to verify →
§ 09 Safety
Safety & side effects
Side effects
- 01Nausea
- 02GI effects typical of incretin class
Contraindications
None specified.
§ 10 Questions
Mazdutide FAQ
- What is Mazdutide?
- Dual GLP-1 / glucagon receptor agonist showing strong weight loss and metabolic effects in late-stage trials, particularly in Asian populations. Mazdutide activates both GLP-1 and glucagon receptors. The glucagon arm is hypothesized to increase energy expenditure and improve hepatic lipid handling, while GLP-1 drives appetite suppression and glycemic control.
- What is Mazdutide used for?
- Reported uses include substantial weight loss in phase iii (glory-1), improvements in hepatic fat and liver enzymes, and glycemic improvements in t2d. Evidence strength is rated Clinical — see the evidence section for detail.
- How is Mazdutide dosed?
- Commonly referenced dosing is 3 – 9 mg weekly, administered SubQ. This is educational reference only; consult a licensed clinician before use.
- How do you reconstitute Mazdutide?
- For Mazdutide, vials commonly come in 10 mg and a common reconstitution is 1 ml BAC water. Use the reconstitution calculator to convert any vial size and water volume into exact insulin-syringe units.
- What are the side effects of Mazdutide?
- Commonly reported side effects include nausea and gi effects typical of incretin class. This list is not exhaustive.
- Is Mazdutide legal?
- Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk. FDA status: Not FDA-approved. Approved in China (2025)..